Clinical Trial Disruption Due to COVID-19: Interpreting and Communicating Data With Regulators

HCG hosts a panel of industry experts to discuss how to interpret data from clinical trials disrupted by the COVID-19 pandemic and how to best communicate these data with regulators. (2020)

66 minute video


Mary Rofael, MD, RAC
President, ProEd Regulatory
Thomas R. Fleming, PhD
Professor, Biostatistics and Statistics, University of Washington
Robert Makuch, PhD
Professor of Biostatistics and Director of the Regulatory Affairs Track, Yale University Schools of Medicine and of Public Health
Kannan Natarajan, PhD
Head of Global Biometrics and Data Management, Pfizer, Inc.
Joanne Palmisano, MD, FACP, FRAPS
Vice President, Head Global Regulatory Strategy, Vertex Pharmaceuticals, Inc
William White, MD
Medical and Scientific Consultant, Professor of Medicine, Calhoun Cardiology Center, University of Connecticut School of Medicine; past president, American Society of Hypertension

More Information

The Collective Intelligence Webinars leverage the global expertise of the Healthcare Consultancy Group (HCG) to provide leading professionals across pharma and biotech with thought-leadership examples of future thinking, collaboration, and communication excellence.

HCG is a global leader in medical communications, comprising 7 interconnected agencies with distinct personalities and complementary skills.

The depth of our expertise allows us to configure custom solutions to meet your scientific, regulatory, and digital needs. Discrete offices and robust processes ensure the confidentiality of your data and programs.

We give your programs the profile they deserve by building your team with you in mind.